关键词：骨髓；造血干细胞；癌症；为白血病；慢性；急性；四种类型
摘 要：Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Types of CLL

Symptoms

Diagnosis

Staging

Management

Key buying criteria

PART 06: Pipeline analysis

Acalabrutinib

TG-1101 + ibrutinib

TGR-1202

Venetoclax + obinutuzumab

Venetoclax + rituximab

REVLIMID

Duvelisib

PART 07: Market landscape

Global CLL therapeutics market

Total addressable market for global CLL therapeutics

Five forces analysis

PART 08: Market segmentation by ROA

Oral

Parenteral

PART 09: Market segmentation by type of molecule

Small molecules

Biologics

PART 10: Geographical segmentation

Global CLL therapeutics market by geographical

segmentation 2015-2020

CLL therapeutics market in Americas

CLL therapeutics market in EMEA

CLL therapeutics market in APAC

PART 11: Market drivers

Special regulatory designations

Recent drug approvals

Application for expanded indication approvals

Increase in patient pool

PART 12: Impact of drivers

PART 13: Market challenges

High cost of therapy

Availability of chemotherapy and off-label drugs

Adverse effects of drugs

Stringent regulatory guidelines

PART 14: Impact of drivers and challenges

PART 15: Market trends

Joint ventures and partnerships

Patient assistance programs

Rise in development of combination therapies

Growing public awareness

PART 16: Vendor landscape

Competitive scenario

Market share analysis 2015

F. Hoffmann-La Roche

AbbVie

Teva Pharmaceuticals

Johnson & Johnson

Gilead Sciences

Novartis

Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio